Aurobindo Pharma Limited (AUROPHARMA.BO)
INR 1082.55
(2.47%)
INR 1082.55
(2.47%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 287.04 Billion | 246.17 Billion | 233.66 Billion | 245.57 Billion | 227.37 Billion | 192.25 Billion |
| Cost of Revenue | 132.36 Billion | 118.99 Billion | 108.15 Billion | 106.11 Billion | 103.12 Billion | 93.29 Billion |
| Gross Profit | 154.68 Billion | 127.17 Billion | 125.51 Billion | 139.46 Billion | 124.25 Billion | 98.96 Billion |
| Operating Expenses | 39.23 Billion | 101.79 Billion | 92.51 Billion | 94.7 Billion | 84.83 Billion | 65.91 Billion |
| Selling, General and Administrative Expenses | 25.02 Billion | 23.48 Billion | 21.77 Billion | 24.29 Billion | 22.04 Billion | 15.75 Billion |
| Research and Development Expenses | 756.3 Million | 395.1 Million | 652.4 Million | 688.1 Million | 1.21 Billion | 756.3 Million |
| Other Expenses | 5.18 Billion | 1.28 Billion | 1.34 Billion | 2.25 Billion | 652.9 Million | 1.01 Billion |
| Cost and Expenses | 245.04 Billion | 220.79 Billion | 200.66 Billion | 200.81 Billion | 187.96 Billion | 159.2 Billion |
| Operating Income | 42.2 Billion | 25.75 Billion | 33.29 Billion | 43.68 Billion | 39 Billion | 30.28 Billion |
| Interest Expense | 2.89 Billion | 1.28 Billion | 368.4 Million | 595.7 Million | 1.41 Billion | 1.5 Billion |
| Income Tax Expense | 12.11 Billion | 6.84 Billion | 7.25 Billion | 20.09 Billion | 8.99 Billion | 7.26 Billion |
| Earnings before Tax | 43.97 Billion | 26.12 Billion | 33.72 Billion | 73.43 Billion | 37.43 Billion | 30.91 Billion |
| Net Income | 31.72 Billion | 19.27 Billion | 26.48 Billion | 53.34 Billion | 28.45 Billion | 23.64 Billion |
| Earnings Per Share Basic | 54.16 | 32.90 | 45.20 | 91.05 | 48.56 | 40.36 |
| Earnings Per Share Diluted | 54.16 | 32.90 | 45.20 | 91.05 | 48.56 | 40.36 |
| Weighted Average Shares Outstanding | 585.85 Million | 585.93 Million | 585.93 Million | 585.93 Million | 585.93 Million | 585.9 Million |
| Weighted Average Shares Outstanding (Diluted) | 585.85 Million | 585.93 Million | 585.93 Million | 585.93 Million | 585.93 Million | 585.93 Million |
| Gross Margin | 0.54 | 0.52 | 0.54 | 0.57 | 0.55 | 0.51 |
| EBIT Margin | 0.22 | 0.16 | 0.20 | 0.22 | 0.22 | 0.21 |
| Profit Margin | 0.11 | 0.08 | 0.11 | 0.22 | 0.13 | 0.12 |
| EBITDA | 61.78 Billion | 40.09 Billion | 45.79 Billion | 85.28 Billion | 48.84 Billion | 39.19 Billion |
| Earnings Before Tax Margin | 0.15 | 0.10 | 0.14 | 0.18 | 0.17 | 0.16 |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 75.67 Billion | 75.8 Billion | 290.01 Billion | 72.71 Billion | 71.5 Billion | 67.9 Billion |
| Cost of Revenue | 45.48 Billion | 44.41 Billion | 180.47 Billion | 31.5 Billion | 32.36 Billion | 31.54 Billion |
| Gross Profit | 30.18 Billion | 31.38 Billion | 109.54 Billion | 41.2 Billion | 39.13 Billion | 36.35 Billion |
| Operating Expenses | 18.02 Billion | 18.05 Billion | 66.33 Billion | 29.42 Billion | 29.28 Billion | 28.11 Billion |
| Selling, General and Administrative Expenses | 14.63 Billion | 18.05 Billion | - | 12.12 Billion | 13.24 Billion | 12.04 Billion |
| Research and Development Expenses | 3.39 Billion | 3.92 Billion | - | 3.98 Billion | 3 Billion | 3.87 Billion |
| Other Expenses | 2.19 Billion | 1.35 Billion | 5.18 Billion | 1.17 Billion | 1.86 Billion | 786.5 Million |
| Cost and Expenses | 63.51 Billion | 62.47 Billion | 246.8 Billion | 60.93 Billion | 61.64 Billion | 59.65 Billion |
| Operating Income | 12.15 Billion | 13.32 Billion | 43.21 Billion | 11.78 Billion | 9.85 Billion | 8.24 Billion |
| Interest Expense | 1.11 Billion | 894.3 Million | 2.89 Billion | 755.5 Million | 681.8 Million | 565.5 Million |
| Income Tax Expense | 4.05 Billion | 3.22 Billion | 12.11 Billion | 3.22 Billion | 3.23 Billion | 2.42 Billion |
| Earnings before Tax | 13.25 Billion | 12.42 Billion | 43.97 Billion | 12.62 Billion | 10.75 Billion | 8.12 Billion |
| Net Income | 9.19 Billion | 9.08 Billion | 31.72 Billion | 9.36 Billion | 7.57 Billion | 5.7 Billion |
| Earnings Per Share Basic | 15.69 | 15.51 | - | 15.98 | 12.92 | 9.74 |
| Earnings Per Share Diluted | 15.69 | 15.51 | - | 15.98 | 12.92 | 9.74 |
| Weighted Average Shares Outstanding | 585.93 Million | 585.93 Million | 585.85 Million | 585.93 Million | 585.93 Million | 585.93 Million |
| Weighted Average Shares Outstanding (Diluted) | 585.93 Million | 585.93 Million | 585.85 Million | 585.93 Million | 585.93 Million | 585.93 Million |
| Gross Margin | 0.40 | 0.41 | 0.38 | 0.57 | 0.55 | 0.54 |
| EBIT Margin | 0.21 | 0.22 | - | 0.24 | 0.22 | 0.19 |
| Profit Margin | 0.12 | 0.12 | 0.11 | 0.13 | 0.11 | 0.08 |
| EBITDA | 16.19 Billion | 16.87 Billion | - | 17.61 Billion | 15.61 Billion | 12.64 Billion |
| Earnings Before Tax Margin | 0.16 | 0.18 | 0.15 | 0.16 | 0.14 | 0.12 |
3075
9385
8030
JASH
4320
PRIMESECU